Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO
Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development. The appointment is part of a planned succession process, with co-founder Dr John McCafferty transitioning from Chief Executive Officer to Chief Technology Officer after having co-founded Maxion, raised $16 million in initial funding, and established its cutting-edge KnotBody® technology.
Prior to joining Maxion, Arndt has served as the Chief Scientific Officer of Affimed and held executive leadership roles as Executive Vice President of R&D at Kymab (acquired by Sanofi) and Chief Development Officer at MorphoSys as well as senior leadership roles at Genentech. During his 25-year career in the pharmaceutical industry, he established a successful track record of advancing therapeutics from research into early and late-stage clinical developments and in building valuable portfolios of drug candidates and pharma partnerships. Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.
Arndt studied medicine in Freiburg, Germany and at the Royal Free Hospital in London. He holds PhD and MD degrees from the University of Freiburg, Germany and a Habilitation in Experimental Medicine degree from Ludwig-Maximilian University Munich. Arndt subsequently practised medicine as a resident physician in gastroenterology at the Charité-Universitätsmedizin in Berlin, Germany, and held a research fellowship from the Crohn’s & Colitis Foundation of America at the University of North Carolina at Chapel Hill before working in the pharmaceutical industry.
Eva-Lotta Allan, Chair of the Board of Directors commented:
Dr John McCafferty, current CEO added:
Dr Arndt Schottelius, incoming CEO said:
Contact
About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.
The Company is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody® technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using state-of-the-art phage and mammalian display technologies. Maxion was founded in 2020 by highly respected biotech entrepreneurs and scientists Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO. Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. Maxion’s portfolio and growth is being advanced by a team of highly experienced leaders in the discovery and development of antibody-based drugs. The Company is based near Cambridge, UK and is backed by international blue-chip investors.
For more information, please visit: https://www.maxiontherapeutics.com/
